Brenntag, the global market leader in chemicals and ingredients distribution, today announced the acquisition of PIC Química e Farmacêutica Ltda. (PIC) and PharmaSpecial Especialidades Químicas e Farmacêuticas Ltda. (PharmaSpecial) in Brazil. This acquisition significantly expands the company’s position in the growing Life Science market in Brazil. PIC and PharmaSpecial are established, family-owned specialty chemicals distributors, serving large customers and national compounding pharmacies in Pharma, Personal Care and other Life Science industries.

Torsten Walz, global president Pharma – Brenntag Specialties, comments: “PIC and PharmaSpecial have built a broad portfolio of world-class suppliers and value-added services which are highly compatible with our global Pharma strategy. I look forward to growing our business in the region to expand on this foundation.”

This acquisition by Brenntag Specialties in Latin America is also an opportunity to expand Brenntag’s global network of Application & Innovation Centers. In addition, the company gains entry into the soft gel capsule market.

“I wholeheartedly welcome and look forward to working with our new colleagues. Growing our footprint in Latin America, better serving our customers and expanding our value-added services capabilities is our ambition, and this transaction is a major step forward”, adds François Bleger, Global president Beauty & Care – Brenntag Specialties.

“Joining Brenntag is a wonderful opportunity to grow what we have built,” comments Fabio Morais, CEO of PIC and PharmaSpecial. “Our dedicated team will be able to better serve our regional customers with the global expertise and network of Application & Innovation Centers we gain from Brenntag. This gives our supply partners a significant global reach. I am really looking forward to seeing what the future holds.”

Founded in 1991 and headquartered in Itapevi, Brazil, the two businesses generated sales of approximately 11 million EUR (~$12.19 million) in 2023. Financial details of the deal are not being disclosed. Closing of the transaction is subject to customary conditions, including regulatory approvals and is expected in Q4 of 2024.

Note: The content of this press release has not been edited by Fibre2Fashion staff.

Fibre2Fashion News Desk (HU)